GEXVal to Exhibit at BioJapan 2025

GEXVal Inc.
October 3, 2025

GEXVal to Showcase AI-Powered Drug Discovery Platform RePhaIND^® at BioJapan 2025

GEXVal Inc. (President and CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan, hereinafter “GEXVal”) is pleased to announce that it will exhibit at BioJapan 2025, to be held at PACIFICO Yokohama (Kanagawa, Japan) from October 8 to 10, 2025.

At the booth, GEXVal will demonstrate its proprietary next-generation drug discovery platform, RePhaIND^{® 1)}, which pioneers the application of Graph Attention Autoencoder (GATE ²⁾ ) technology—a cutting-edge artificial intelligence (AI) approach in the field of drug discovery.

On the final day, October 10, GEXVal will also host a presentation and panel discussion titled "Strategic Utilization of Australian Clinical Development: Early Development Approaches to Maximize Value Creation." For additional details, please see our news release.

[Event Overview]
BioJapan is Asia's one of the largest biotechnology and life sciences exhibition. The event brings together pharmaceutical companies, startups, research institutions, medical device manufacturers, investors and government agencies from Japan and abroad, offering abundant opportunities for industrialization, commercialization, and open innovation.

**Presentation Details**

[CEO Statement]
President and CEO Dr. Juran Kato commented: "Our purpose is to strive to deliver medicines—as quickly as possible—to patients and their families awaiting effective treatments. At this year's BioJapan, we are truly excited to share the experience and learnings from our Australian clinical trials through our seminars and panel discussions with the drug discovery ecosystem that shares our mission. At our booth, we will showcase our newest R&D achievements and explore the potential of AI-powered drug discovery technologies, while seeking new possibilities for collaboration."

[About GEXVal]
GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology, we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

1) About RePhaIND^®：Revolutionary Pharmacoinformatics to Find IND (Investigational New Drug)
RePhaIND^® is GEXVal's proprietary AI-driven drug discovery platform with three key features:

• EMPOWER: Discover hidden relationships between drug candidates and diseases
• ACCELERATE: Dramatically improve efficiency compared to conventional methods
• REVOLUTIONIZE: Enable new approaches to unmet medical needs, particularly in rare diseases, bringing a paradigm shift to the drug discovery process

RePhaIND^® is a registered trademark of GEXVal Inc. in Japan, China, Hong Kong, Korea, Australia, Europe, UK, and US and a trademark in other countries and regions.

2) About Graph Attention Autoencoder（GATE）
Graph Neural Networks (GNNs) are AI technologies that learn patterns from various "connections" in data. In particular, Graph Attention Network (GAT) is widely used in everyday services such as social media recommendations and logistics route optimization. Notably, Graph Attention Autoencoder (GATE), which GEXVal pioneered in drug discovery, has previously been limited to specific applications in life sciences, such as protein structure prediction. By innovatively applying GATE technology to the entire drug discovery process, GEXVal enables the discovery of novel therapeutic candidates that would otherwise remain unidentified through conventional methods.

For further information:
Head of Corporate Office
Atsushi Sugizaki
info@gexval.com